Context Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

CNTX$0.19-6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Six months ended June 30,
	2024	2023
Cash flows from operating activities:
Net loss	$(5,922,303)	$(11,319,639)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	397,044	565,865
Depreciation and amortization expense	5,136	6,387
Reduction in the carrying amount of operating lease right-of-use asset	—	44,445
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	435,751	(215,243)
Other assets	—	8,750
Accounts payable	(1,816,135)	254,526
Accrued expenses and other current liabilities	(815,867)	342,458
Operating lease liability	—	(47,111)
Cash used in operating activities	(7,716,374)	(10,359,562)
Cash flows from financing activities:
Proceeds from the sale of common stock and prefunded warrants, net	94,803,379	—
Cash provided by financing activities	94,803,379	—
Net increase (decrease) in cash and cash equivalents	87,087,005	(10,359,562)
Cash and cash equivalents at beginning of period	14,449,827	35,497,445
Cash and cash equivalents at end of period	$101,536,832	$25,137,883
Supplemental disclosure of non-cash activities:
Unpaid offering costs in accounts payable	$44,632	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.